The Psychedelics Newsletter

The PSYCH Symposium is set to bring together leaders from across the international psychedelics industry who are set to discuss and debate the most important issues facing the sector.

With less than a month to go, there is only a limited amount of time to secure your place at The Psych Symposium. You can also catch up with the biggest news stories from across the industry, here.

Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers.

The Psychedelics as Medicine Report: Second Edition has been launched by PSYCH. The report delivers a comprehensive overview of the entire psychedelics sector and can be accessed in this week’s issue.

An Oregonian Congressman supports a measure for the legalisation of psilocybin therapy and psychedelic decriminalisation awaits a response from the Canadian government.

A petition to legalise natural psychedelics in Canada reaches 13,000 signatures, and a Congressman has said psychedelics show promise in treating PTSD as Oakland activists also unveil guidelines for psychedelic healing ceremonies.

Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.

An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.

Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.